Compare DexCom, Inc. (DXCM) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs IQIYI Inc - ADR — how do they compare? DexCom, Inc. trades at $85.15 (market cap $31.86B), while IQIYI Inc - ADR trades at $1.05 (market cap $974.67M). The key difference: DexCom, Inc. is far larger — about 32.7× IQIYI Inc - ADR's market cap, and DexCom, Inc. is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and IQIYI Inc - ADR for 55 Days on average.
| DXCM | IQ | |
|---|---|---|
Market Cap | $31.86B | $974.67M |
Volume | 3,607,070 | 4,964,108 |
Sector | Health | Media |
52-Week High | $92.34 | $2.35 |
52-Week Low | $54.84 | $0.86 |
Typical Hold Time | 62 Days | 55 Days |
Enterprise Value | $31.32B | $2.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
iQIYI (IQ) trades at $1.015, up 0.5% with neutral technical signals. The company reported Q2 2026 revenue of $6.3 billion (up 1% sequentially) but posted a net loss of -$206 million in 2025. Valuation metrics show mixed signals with low P/S (0.25) and P/B (0.52) ratios but elevated P/E (144.05) due to negative earnings. Recent news highlights AI-driven content expansion with over 350 new titles announced for 2026-2027.
Investment outlook remains cautious despite analyst consensus leaning bullish (50% buy ratings). The streaming business faces revenue pressure with 2026 projections showing -3.22% net margin, though AI content initiatives could improve cost structure. Key risks include Chinese regulatory environment and streaming competition. Institutional sentiment appears divided given mixed technical indicators and fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
